Description of use

Pi™ software has the following expected clinical benefits:

• Identify patients not at risk of csPCa (clinically significant prostate cancer) through provision of a risk score that can be considered as part of the decision to biopsy.
• Find more significant cancer, by highlighting high-risk lesions that radiologists might miss, enabling more accurate targeting.
• Speed up the process, by facilitating assessment and segmentation tasks through provision of candidate prostate and lesion segmentations.
• Identify estimated volume of prostate and lesions.

Additional benefits including assisting with teaching non-experienced radiologists how to report prostate MRI, and reducing clinical workload by automating volume calculation and structured reporting.